South Korea’s MFDS approved Curocell’s Rimqarto (anbal-cel), positioning it as the first homegrown CAR T therapy in the country for advanced diffuse large B-cell lymphoma. The approval covers patients with advanced DLBCL, expanding the local commercial CAR-T footprint as global players continue to invest in capacity and regional development pathways.